Headache in Multiple Sclerosis: A Narrative Review
- PMID: 38674218
- PMCID: PMC11052044
- DOI: 10.3390/medicina60040572
Headache in Multiple Sclerosis: A Narrative Review
Abstract
Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system characterized by autoimmune-mediated damage to oligodendrocytes and subsequent myelin destruction. Clinical implications: Clinically, the disease presents with many symptoms, often evolving over time. The insidious onset of MS often manifests with non-specific symptoms (prodromal phase), which may precede a clinical diagnosis by several years. Among them, headache is a prominent early indicator, affecting a significant number of MS patients (50-60%). Results: Headache manifests as migraine or tension-type headache with a clear female predilection (female-male ratio 2-3:1). Additionally, some disease-modifying therapies in MS can also induce headache. For instance, teriflunomide, interferons, ponesimod, alemtuzumab and cladribine are associated with an increased incidence of headache. Conclusions: The present review analyzed the literature data on the relationship between headache and MS to provide clinicians with valuable insights for optimized patient management and the therapeutic decision-making process.
Keywords: headache; migraine; multiple sclerosis; prodromal syndrome; tension-type headache.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.Medicine (Baltimore). 2021 Dec 23;100(51):e28246. doi: 10.1097/MD.0000000000028246. Medicine (Baltimore). 2021. PMID: 34941096 Free PMC article.
-
Teriflunomide-related development of inverse psoriasis and worsening of pre-existing plaque psoriasis.Dermatol Online J. 2024 Aug 15;30(4). doi: 10.5070/D330464111. Dermatol Online J. 2024. PMID: 39644471
-
Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.Sci Rep. 2021 Jun 15;11(1):12533. doi: 10.1038/s41598-021-91912-x. Sci Rep. 2021. PMID: 34131191 Free PMC article.
-
Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.Eur J Med Chem. 2013 Feb;60:170-86. doi: 10.1016/j.ejmech.2012.10.055. Epub 2012 Nov 23. Eur J Med Chem. 2013. PMID: 23291119 Review.
-
Update on treatment in multiple sclerosis.Presse Med. 2021 Jun;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Epub 2021 May 24. Presse Med. 2021. PMID: 34033862 Review.
Cited by
-
Elevated Oxidative Stress in Patients with Coexisting Multiple Sclerosis and Migraine: A Cross-Sectional Study.Antioxidants (Basel). 2025 Apr 24;14(5):511. doi: 10.3390/antiox14050511. Antioxidants (Basel). 2025. PMID: 40427393 Free PMC article.
References
-
- MS International Federation Map View. 2023. [(accessed on 11 December 2023)]. Available online: https://www.atlasofms.org/map/global/epidemiology/number-of-people-with-ms.
-
- Marrodan M., Bensi C., Pappolla A., Rojas J., Gaitán M., Ysrraelit M., Negrotto L., Fiol M., Patrucco L., Cristiano E., et al. Disease activity impacts disability progression in primary progressive multiple sclerosis. Mult. Scler. Relat. Disord. 2019;39:101892. doi: 10.1016/j.msard.2019.101892. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical